Literature DB >> 23065631

Differential methylation of E2 binding sites in episomal and integrated HPV 16 genomes in preinvasive and invasive cervical lesions.

Arkom Chaiwongkot1, Svetlana Vinokurova, Chamsai Pientong, Tipaya Ekalaksananan, Bunkerd Kongyingyoes, Pilaiwan Kleebkaow, Bandit Chumworathayi, Natcha Patarapadungkit, Miriam Reuschenbach, Magnus von Knebel Doeberitz.   

Abstract

Enhanced expression of the HPV 16 E6-E7 oncogenes may trigger neoplastic transformation of the squamous epithelial cells at the uterine cervix. The HPV E2 protein is a key transcriptional regulator of the E6-E7 genes. It binds to four E2 binding sites (E2BSs 1-4) in the viral upstream regulatory region (URR). Modification of E2 functions, for example, by methylation of E2BSs is hypothesized to trigger enhanced expression of the viral E6-E7 oncogenes. In the majority of HPV-transformed premalignant lesions and about half of cervical carcinomas HPV genomes persist in an extra-chromosomal, episomal state, whereas they are integrated into host cells chromosomes in the remaining lesions. Here we compared the methylation profile of E2BSs 1-4 of the HPV 16 URR in a series of 18 HPV16-positive premalignant lesions and 33 invasive cervical cancers. CpGs within the E2BSs 1, 3, and 4 were higher methylated in all lesions with only episomal HPV16 genomes compared with lesions displaying single integrated copies. Samples with multiple HPV16 integrated copies displayed high methylation levels for all CpGs suggesting that the majority of multiple copies were silenced by extensive methylation. These data support the hypothesis that differential methylation of the E2BSs 1, 3 and 4 is related to the activation of viral oncogene expression in cervical lesions as long as the viral genome remains in the episomal state. Once the virus becomes integrated into host cell chromosomes these methylation patterns may be substantially altered due to complex epigenetic changes of integrated HPV genomes.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065631     DOI: 10.1002/ijc.27906

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  46 in total

1.  Epigenetics of human papillomaviruses.

Authors:  Eric Johannsen; Paul F Lambert
Journal:  Virology       Date:  2013-08-13       Impact factor: 3.616

2.  Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines.

Authors:  Takashi Hatano; Daisuke Sano; Hideaki Takahashi; Hiroshi Hyakusoku; Yasuhiro Isono; Shoko Shimada; Kae Sawakuma; Kentaro Takada; Ritsuko Oikawa; Yoshiyuki Watanabe; Hiroyuki Yamamoto; Fumio Itoh; Jeffrey N Myers; Nobuhiko Oridate
Journal:  Int J Cancer       Date:  2017-01-09       Impact factor: 7.396

Review 3.  Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA.

Authors:  Tandrima Mitra; Selvakumar Elangovan
Journal:  Mol Cell Biochem       Date:  2021-08-28       Impact factor: 3.396

Review 4.  Epigenetic and Transcriptomic Regulation Landscape in HPV+ Cancers: Biological and Clinical Implications.

Authors:  Rosario Castro-Oropeza; Patricia Piña-Sánchez
Journal:  Front Genet       Date:  2022-06-14       Impact factor: 4.772

5.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

6.  CpG methylation in human papillomavirus (HPV) type 31 long control region (LCR) in cervical infections associated with cytological abnormalities.

Authors:  Brigitta László; Annamária Ferenczi; László Madar; Eszter Gyöngyösi; Anita Szalmás; Levente Szakács; György Veress; József Kónya
Journal:  Virus Genes       Date:  2016-04-20       Impact factor: 2.332

7.  Human papillomaviruses: research priorities for the next decade.

Authors:  Erika Langsfeld; Laimonis A Laimins
Journal:  Trends Cancer       Date:  2016-05

Review 8.  The papillomavirus E2 proteins.

Authors:  Alison A McBride
Journal:  Virology       Date:  2013-07-10       Impact factor: 3.616

9.  Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions.

Authors:  Alyssa M Cornall; Jennifer M Roberts; Monica Molano; Dorothy A Machalek; Samuel Phillips; Richard J Hillman; Andrew E Grulich; Fengyi Jin; I Mary Poynten; David J Templeton; Suzanne M Garland; Sepehr N Tabrizi
Journal:  BMJ Open       Date:  2015-08-26       Impact factor: 2.692

10.  Human Papillomavirus Type 18 cis-Elements Crucial for Segregation and Latency.

Authors:  Mart Ustav; Fernando Rodriguez Castaneda; Tormi Reinson; Andres Männik; Mart Ustav
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.